No, atovaquone-proguanil (Malarone) has no other FDA-approved indications beyond malaria prophylaxis and treatment.
Atovaquone-proguanil is exclusively indicated for the prevention and treatment of malaria caused by Plasmodium species, particularly P. falciparum. There are no other approved therapeutic uses for this medication.
Approved Indications
The drug has two specific malaria-related indications:
1. Malaria Prophylaxis
- Prevention of P. falciparum malaria in travelers to endemic areas 1, 2
- Particularly effective in areas with chloroquine-resistant and multi-drug resistant malaria 3, 4
- Protective efficacy exceeds 95% for P. falciparum and approximately 84% for P. vivax 5
2. Malaria Treatment
- Treatment of acute, uncomplicated P. falciparum malaria 1, 2
- Cure rates consistently exceed 93% in clinical trials 3
- Can be used as first-line treatment in non-endemic settings or as second-line when artemisinin-based combinations are unavailable 1
Important Limitations
The drug is less effective against non-falciparum species (P. vivax, P. ovale, P. malariae, P. knowlesi), where chloroquine remains the reference treatment 6. While atovaquone-proguanil provides causal prophylaxis against P. vivax liver-stage schizonts, it does not prevent late reactivation from hypnozoites, resulting in relapse rates of approximately 50% 7.
Clinical Context
The medication is positioned as:
- First-line option for travelers requiring short-term prophylaxis in chloroquine-resistant areas 1
- Second-line treatment when artemisinin-based combinations or mefloquine are contraindicated or unavailable 1, 6
- Alternative therapy in complicated malaria when artesunate is not available 1
There is no evidence or approval for using atovaquone-proguanil for any non-malarial parasitic infections, bacterial infections, or other conditions.